Exelixis

US · EXEL #1156 by market cap Listed 1970

58.44 +0.11 +0.19%

Live - 5344 symbols - heartbeat 539s ago · 2026-10-08 07:14

Pre-market 59.00 +0.96%

After-hours 58.44 0.00%

Overnight 58.44 0.00%

Market cap: 14.48B
P/E (TTM): 18.38
P/B: 7.85
EPS: 2.78
Div yield: 0.00%
52W pos: 90%

Reader sentiment Are you bullish or bearish on EXEL?

Anonymous reader poll. Unscientific, not investment advice.

About Exelixis

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Founded: 1994
CEO: Dr. Michael M. Morrissey, PhD
Employees: 4,600
Headquarters: Alameda, California, United States of America
Fiscal year end: 01-01
Website: exelixis.com

Company profile

Exchange: US
Symbol: EXEL
Market-cap rank: #1156
Listing date: 1970-01-01
Market cap: 14.48B
Float cap: 12.48B
Shares out: 247.78M
Float shares: 213.60M

Sectors & themes

Biotechnology Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:14:20 · For reference only, not investment advice and not tailored to your situation.